Key result
Loss-of-function mutations in Nav1.4 cause a spectrum of neuromuscular disorders characterized by muscle weakness, proposed to be named sodium channel weakness (SCW).
Why the study?
Although SCN4A loss-of-function mutations cause neuromuscular disorders with muscle weakness, their functional consequences in myofibers remain poorly understood, and developing therapies to counteract this loss of function represents a new challenge.
This review highlights the emerging clinical spectrum of sodium channel weakness caused by Nav1.4 loss-of-function mutations and the need for novel therapeutic strategies.
May aid diagnosis of unexplained weakness; leaves open targeted therapies for Nav1.4 loss-of-function.
The voltage-gated sodium channel Na v 1.4 is a major actor in the excitability of skeletal myofibers, driving the muscle force in response to nerve stimulation. Supporting further this key role, mutations in SCN4A , the gene encoding the pore-forming α subunit of Na v 1.4, are responsible for a clinical spectrum of human diseases ranging from muscle stiffness (sodium channel myotonia, SCM) to muscle weakness. For years, only dominantly-inherited diseases resulting from Na v 1.4 gain of function (GoF) were known, i.e. , non-dystrophic myotonia (delayed muscle relaxation due to myofiber hyperexcitability), paramyotonia congenita and hyperkalemic or hypokalemic periodic paralyses (episodic flaccid muscle weakness due to transient myofiber hypoexcitability). These last 5 years, SCN4A mutations inducing Na v 1.4 loss of function (LoF) were identified as the cause of dominantly and recessively-inherited disorders with muscle weakness: periodic paralyses with hypokalemic attacks, congenital myasthenic syndromes and congenital myopathies. We propose to name this clinical spectrum sodium channel weakness (SCW) as the mirror of SCM. Na v 1.4 LoF as a cause of permanent muscle weakness was quite unexpected as the Na + current density in the sarcolemma is large, securing the ability to generate and propagate muscle action potentials. The properties of SCN4A LoF mutations are well documented at the channel level in cellular electrophysiological studies However, much less is known about the functional consequences of Na v 1.4 LoF in skeletal myofibers with no available pertinent cell or animal models. Regarding the therapeutic issues for Na v 1.4 channelopathies, former efforts were aimed at developing subtype-selective Na v channel antagonists to block myofiber hyperexcitability. Non-selective, Na v channel blockers are clinically efficient in SCM and paramyotonia congenita , whereas patient education and carbonic anhydrase inhibitors are helpful to prevent attacks in periodic paralyses. Developing therapeutic tools able to counteract Na v 1.4 LoF in skeletal muscles is then a new challenge in the field of Na v channelopathies. Here, we review the current knowledge regarding Na v 1.4 LoF and discuss the possible therapeutic strategies to be developed in order to improve muscle force in SCW.
No takes yet. Share an insight, caveat, or question.
Nicole et al. (2021) conducted a review in Nav1.4 channelopathies (Neuromuscular diseases). Nav1.4 loss-of-function mutations was evaluated. Loss-of-function mutations in Nav1.4 cause a spectrum of neuromuscular disorders characterized by muscle weakness, proposed to be named sodium channel weakness (SCW).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: